Tag: Pharmaceuticals
Review of Reverse-Payment Agreements: The Agencies, the Courts, Congress, and the...
Elai Katz, William Rooney, Nov 01, 2009
Two bills seeking to ban reverse-payment agreements are currently pending in Congress, and the European Commission has declared...
Dominant Firms’ Duties to Deal with Pharmaceutical Parallel Traders Following Glaxo...
Louise Macnab, Robert O'Donoghue, Apr 15, 2009
EU competition policy on dominant firms and pharmaceutical parallel trade wholesalers taking advantage of arbitrage possibilities to export...
The Intersection of Antitrust, Patents, and FDA Law: The TriCor Litigation
This article is part of a Chronicle. See more from this Chronicle
Richard Epstein, Mar 26, 2009
The purpose of this brief essay is to address...
From Walker Process to In re DDAVP: Should Direct Purchasers Have...
This article is part of a Chronicle. See more from this Chronicle
Aidan Synnott, Nov 29, 2008
In In re: DDAVP Direct Purchaser Antitrust Litigation, decided...
Innovation Markets after Genzyme/Novazyme
This article is part of a Chronicle. See more from this Chronicle
Richard Gilbert, Jul 12, 2008
The U.S. Federal Trade Commission alleged adverse effects on...
